sovaldi tablet
gilead sciences canada inc - sofosbuvir - tablet - 400mg - sofosbuvir 400mg - miscellaneous antivirals
epclusa tablet
gilead sciences canada inc - sofosbuvir; velpatasvir - tablet - 400mg; 100mg - sofosbuvir 400mg; velpatasvir 100mg - hcv polymerase inhibitors
harvoni tablet
gilead sciences canada inc - sofosbuvir; ledipasvir - tablet - 400mg; 90mg - sofosbuvir 400mg; ledipasvir 90mg - hcv polymerase inhibitors
harvoni tablets ledipasvir 90 mg/ sofosbuvir 400 mg
gilead sciences, inc, usa - ledipasvir 90mg/sofosbuvir 400mg - tablets - ledipasvir 90 mg/ sofosbuvir 400 mg
vosevi sofosbuvir (400 mg), velpatasvir (100 mg), voxilaprevir (100 mg) tablet bottle
gilead sciences pty ltd - voxilaprevir, quantity: 100 mg; velpatasvir, quantity: 100 mg; sofosbuvir, quantity: 400 mg - tablet - excipient ingredients: lactose monohydrate; copovidone; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - vosevi (sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination) is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adult patients, without cirrhosis or with compensated cirrhosis, who have: - genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; - genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties, clinical trials).
myoview
eldan electronic instruments co ltd, israel - tetrofosmin - lyophilized powder for injection - tetrofosmin 0.23 mg/vial - indicated as an adjunct in the diagnosis and localization of myocardial ischaemia or infarction. myoview is indicated as an adjunct to the initial assessments (e.g. palpation mammography or alternative imaging modalities and/or cytology) in characterisation of malignancy of suspected breast lesions where all these other recommended tests were inconclusive.
myoview for injection 0.23 mgvial
ge healthcare pte. ltd. - tetrofosmin (as tetrofosmin sulphosalicylate) - injection, powder, for solution - 0.23 mg/vial - tetrofosmin (as tetrofosmin sulphosalicylate) 0.23 mg/vial
myoview powder for solution
ge healthcare canada inc - tetrofosmin - powder for solution - 0.23mg - tetrofosmin 0.23mg - roentgenography
myoview 30ml powder for solution
ge healthcare canada inc - tetrofosmin - powder for solution - 1.38mg - tetrofosmin 1.38mg - roentgenography
sovaldi 400mg tablets
gilead sciences international ltd - sofosbuvir - tablet - 400mg